You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Citalopram, but not interpersonal psychotherapy, improves major depression in people with coronary artery disease

http://dx.doi.org/10.1136/ebmh.10.3.80

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Lesperance F, Frasure-Smith N, Koszycki D, et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: The Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial. JAMA 2007;297:367–79.OpenUrlCrossRefPubMedWeb of Science

    Q Are citalopram or interpersonal psychotherapy more effective than placebo or clinical management for major depression in people with coronary artery disease?

    METHODS

    Embedded ImageDesign:

    Randomised controlled 2×2 factorial trial.

    Embedded ImageAllocation:

    Concealed.

    Embedded ImageBlinding:

    Double blind for citalopram and placebo; single blind for interpersonal psychotherapy (IPT) or clinical management (assessors blind).

    Embedded ImageFollow-up period:

    Twelve weeks (treatment period only).

    Embedded ImageSetting:

    Nine academic centres, Canada; May 2002 to March 2006.

    Embedded ImagePatients:

    284 outpatients (⩾18 years old) with DSM-IV major depression for ⩾4 weeks, Hamilton Depression rating scale (HAM-D) score ⩾20, and established coronary artery disease (previous myocardial infarction or revascularisation; or angiographic evidence of ⩾50% stenosis in ⩾1 major coronary artery). Main exclusions: depression with psychotic features; bipolar disorder; substance abuse; serious suicidal risk; taking antidepressants, anticonvulsants, lithium, or undergoing psychotherapy; previous non-response to citalopram or IPT; ⩾2 …

    View Full Text

    Footnotes

    • For correspondence: François Lespérance, MD, Centre Hospitalier de l’Université de Montréal, 1560 Sherbrooke E, Montreal, Quebec, Canada H2L 4M1; francois.lesperance{at}umontreal.ca

    • Competing interests: None.

    • Sources of funding: Canadian Institutes of Health Research (CIHR) Clinical Trials Programme, Fondation du Centre Hospitalier de l’Université de Montréal, and the Fondation de l’Institut de Cardiologie de Montréal.

    Footnotes